NicholasKaryotakisMD

Gastroenterology • Los Angeles, CA

Physician

Join to view full profile

Dr. Karyotakis is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Karyotakis' full profile

Already have an account?

Office
2080 Century Park East
#1206
Los Angeles, CA 90067
Phone(310) 282-0525

Fax(310) 201-0662
Is this information wrong?

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Gastroenterology, 1996 - 1999
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1993 - 1996
University of Texas Health Science Center at HoustonPost-Doctoral Fellowship, Infectious Disease, 1991 - 1993
University of Crete School of Health SciencesClass of 1991

Certifications & Licensure

CA State Medical License 1996 - 2022

Clinical Trials

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease Start of enrollment: 2008 Dec 01
Completed
Phase 3
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis Start of enrollment: 2009 Jan 01
Completed
Phase 3
Efficacy and Safety Study With Diltiazem Hydrochloride Cream to Treat Anal Fissures Start of enrollment: 2012 Oct 01
Completed
Phase 3
A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors Start of enrollment: 2014 May 21
Completed
Phase 3
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment Start of enrollment: 2015 Sep 22
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Efficacy of continuous flucytosine infusion against Candida lusitaniae in experimental hematogenous murine candidiasis.
Karyotakis, N. C., Anaissie, E. J.> ;Antimicrob Agents Chemother. 1996 Dec
Effects of cyclophosphamide and ceftriaxone on gastrointestinal colonization of mice by Candida albicans.
Samonis, G., Karyotakis, N. C., Anaissie, E. J., Barbounakis, E., Maraki, S., Tselentis, Y., Bodey, G. P.> ;Antimicrob Agents Chemother. 1996 Sep
Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice.
Karyotakis, N. C., Anaissie, E. J., Hachem, R., Dignani, M. C., Samonis, G.> ;J Infect Dis. 1993 Nov
Correlation between in vitro and in vivo activity of antifungal agents against Candida species.
Anaissie, E. J., Karyotakis, N. C., Hachem, R., Dignani, M. C., Rex, J. H., Paetznick, V.> ;J Infect Dis. 1994 Aug
Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic mice.
Karyotakis, N. C., Anaissie, E. J.> ;Antimicrob Agents Chemother. 1994 Nov
Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis.
Anaissie, E. J., Hachem, R., Karyotakis, N. C., Gokaslan, A., Dignani, M. C., Stephens, L. C., Tin-U, C. K.> ;Antimicrob Agents Chemother. 1994 Nov
SCH 51048, a new antifungal triazole active against hematogenous Candida krusei infections in neutropenic mice.
Karyotakis, N. C., Dignani, M. C., Anaissie, E. J.> ;Antimicrob Agents Chemother. 1995 Mar
Activities of D0870, a novel triazole, against Candida lusitaniae and Trichosporon beigelii in experimental murine infections.
Karyotakis, N. C., Dignani, M. C., Hachem, R., Anaissie, E. J.> ;Antimicrob Agents Chemother. 1995 Feb
Join now to see all

Research History

P.I.IBD vedolizumab IBD ETRO2007 - 2019

Hospital Affiliations

Cedars-Sinai Medical CenterLos Angeles, California
Harbor-UCLA Medical CenterTorrance, California
Olympia Medical CenterLos Angeles, California
Providence Saint John's Health CenterSanta Monica, California